Quercetin Intake and Absolute Telomere Length in Patients with Type 2 Diabetes Mellitus: Novel Findings from a Randomized Controlled Before-and-After Study.

hypoglycemic effect integrated care nutraceutical nutri-senotherapy phytotherapy quercetin randomized trial senolytic telomere length type 2 diabetes mellitus

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
29 Aug 2024
Historique:
received: 01 08 2024
revised: 22 08 2024
accepted: 27 08 2024
medline: 28 9 2024
pubmed: 28 9 2024
entrez: 28 9 2024
Statut: epublish

Résumé

Telomeres, the protective chromosomal ends, progressively shorten and potentially are implicated in the pathogenesis of age-related diseases. In type 2 diabetes (T2DM), telomere shortening may play an important role, but the whole 'picture' remains limited. From a therapeutic perspective, the phytonutrient quercetin appears to be clinically effective and safe for patients with T2DM. Considering the above, we aimed to examine whether quercetin could interfere with telomere length (TL) dynamics. One hundred patients with T2DM on non-insulin medications registered within a primary healthcare facility were stratified by age and sex and randomly assigned to either standard care or standard care plus quercetin (500 mg/day) for 12 weeks, succeeded by an 8-week washout period and another 12 weeks of supplementation. Of the 88 patients completing the trial, 82 consented to blood sampling for TL measurements. Health assessments and whole blood absolute TL measurements using quantitative polymerase chain reaction (qPCR) were conducted at baseline and study end, and the findings of this subcohort are presented. Quercetin supplementation was associated with a significant increase in mean TL (odds ratio ≥ 2.44;

Identifiants

pubmed: 39338301
pii: ph17091136
doi: 10.3390/ph17091136
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Aikaterini E Mantadaki (AE)

Clinic of Social and Family Medicine, Department of Social Medicine, School of Medicine, University of Crete, 70013 Heraklion, Greece.

Stella Baliou (S)

Laboratory of Toxicology, Medical School, University of Crete, 71003 Heraklion, Greece.

Manolis Linardakis (M)

Clinic of Social and Family Medicine, Department of Social Medicine, School of Medicine, University of Crete, 70013 Heraklion, Greece.

Elena Vakonaki (E)

Laboratory of Toxicology, Medical School, University of Crete, 71003 Heraklion, Greece.

Manolis N Tzatzarakis (MN)

Laboratory of Toxicology, Medical School, University of Crete, 71003 Heraklion, Greece.

Aristides Tsatsakis (A)

Laboratory of Toxicology, Medical School, University of Crete, 71003 Heraklion, Greece.

Emmanouil K Symvoulakis (EK)

Clinic of Social and Family Medicine, Department of Social Medicine, School of Medicine, University of Crete, 70013 Heraklion, Greece.

Classifications MeSH